28 results on '"Barbarot S"'
Search Results
2. COVID-19 lockdown induced acral dermatosis in children.
- Author
-
Bodak N, Chiaverini C, and Barbarot S
- Subjects
- Child, Child, Preschool, Female, Humans, Male, Posture, COVID-19, Quarantine, Skin Diseases etiology
- Published
- 2020
- Full Text
- View/download PDF
3. [Cutaneous hypereosinophilia… Hypereosinophilic syndromes].
- Author
-
Aubert H, Hamidou M, Barbarot S, Piriou N, Lefebvre M, and Néel A
- Subjects
- Heart Diseases diagnostic imaging, Heart Diseases etiology, Humans, Hypereosinophilic Syndrome blood, Hypereosinophilic Syndrome etiology, Hypereosinophilic Syndrome pathology, Skin Diseases etiology, Skin Diseases pathology, Hypereosinophilic Syndrome diagnosis, Skin Diseases diagnosis
- Published
- 2020
- Full Text
- View/download PDF
4. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
- Author
-
Leducq S, Caille A, Barbarot S, Bénéton N, Bessis D, Boccara O, Bursztejn AC, Chiaverini C, Dompmartin A, Droitcourt C, Gissot V, Goga D, Guibaud L, Herbreteau D, Le Touze A, Léauté-Labrèze C, Lorette G, Mallet S, Martin L, Mazereeuw-Hautier J, Phan A, Plantin P, Quéré I, Vabres P, Bourgoin H, Giraudeau B, and Maruani A
- Subjects
- Administration, Cutaneous, Adolescent, Adult, Child, Clinical Trials, Phase II as Topic, Double-Blind Method, France, Humans, Lymphangiectasis pathology, Lymphatic Abnormalities drug therapy, Lymphatic Abnormalities pathology, Multicenter Studies as Topic, Quality of Life, Randomized Controlled Trials as Topic, Skin Diseases pathology, TOR Serine-Threonine Kinases metabolism, Treatment Outcome, Young Adult, Dermatologic Agents administration & dosage, Lymphangiectasis drug therapy, Sirolimus administration & dosage, Skin Diseases drug therapy
- Abstract
Background: Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions in children and adults. They present as clusters of vesicles full of lymph and blood to various extents, inducing maceration, esthetic impairment, pain, and impaired quality of life. The treatment is challenging. Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) involved in angio-lymphangiogenesis. Topical sirolimus has recently been reported as effective in a few reports of patients with CMLMs. The objective is to compare the efficacy and safety of a 12-week application of 0.1% topical sirolimus versus topical vehicle in CMLMs in children and adults., Methods: This French blinded multicenter within-person randomized controlled phase 2 trial aims to include 55 patients aged ≥ 6 years who have a primary CMLM. The CMLM will be divided into two equal areas that will be randomly allocated to 0.1% topical sirolimus or topical vehicle applied for 12 weeks. At the end of the 12-week period, the patient/parent will treat the whole area of CMLM with 0.1% topical sirolimus on remaining lesions, for eight more weeks. Patients will be seen at week 20 (treatment will be stopped) and at month 12 to evaluate long-term efficacy. The primary outcome will be improvement of the CMLM in the area treated with topical sirolimus compared to the area treated with topical vehicle by the investigator physician (blinded to the treatment) with the Physician Global Assessment score at week 12. Secondary outcomes will include: assessment of efficacy by independent experts on the basis of standardized photographs; impact on quality of life; efficacy for oozing, bleeding, erythema, and thickness evaluated by the investigators; and global efficacy as well as efficacy for functional and aesthetic impairment evaluated by the patient. Systemic passage of sirolimus will be measured at weeks 6, 12, and 20, and at week 16 for CMLMs ≥ 900 cm
2 ., Discussion: For patients with CMLMs, topical sirolimus could be a non-invasive and well-tolerated therapeutic option. If the trial demonstrates efficacy and safety of this treatment, this result will lead to a real change in the management of this condition, and 0.1% sirolimus cream would become the first-line treatment., Trial Registration: ClinicalTrials.gov, NCT03972592. Registered on 3 June 2019. EU Clinical Trials Register EudraCT, 2018-001359-11.- Published
- 2019
- Full Text
- View/download PDF
5. Age-specific characteristics of neutrophilic dermatoses and neutrophilic diseases in children.
- Author
-
Bucchia M, Barbarot S, Reumaux H, Piram M, Mahe E, Mallet S, Balguerie X, Phan A, Lacour JP, Decramer S, Hatchuel Y, Jean S, Begon E, Joubert A, Merlin E, Wallach D, Meinzer U, and Bourrat E
- Subjects
- Adolescent, Age Factors, Child, Child, Preschool, Female, Humans, Infant, Male, Retrospective Studies, Skin Diseases classification, Skin Diseases immunology, Leukocyte Disorders diagnosis, Neutrophils, Skin Diseases diagnosis
- Abstract
Background: Our suggested 'modern' concepts of 'neutrophilic dermatoses' (ND) and 'neutrophilic disease' were based on observations in adult patients and have not been studied in paediatric patients. Only a minority of ND occurs in children, and little is known about age-specific characteristics., Objectives: To describe age-specific characteristics of ND in children and to study whether our suggested 'modern' classification of ND may be applied to children., Methods: We conducted a retrospective multicentre study in a French cohort of 27 paediatric patients diagnosed with pyoderma gangrenosum (PG) or Sweet's syndrome (SS)., Results: Demographics and distribution of typical/atypical forms were similar in patients diagnosed with PG and SS. Atypical ND were more frequent in infants (90%), when compared to young children (60%) and adolescents (33%). Neutrophilic disease was observed in 17/27 patients and was most frequent in infants. Neutrophilic disease of the upper respiratory tract, as well as cardiac neutrophilic disease, was only observed in infants, whereas other locations were similarly found in infants, young children and adolescents. In infants and young children, ND were associated with a large spectrum of general diseases, whereas in adolescents associations were limited to inflammatory bowel disease and Behçet's disease., Conclusions: Our study describes the concept of ND in paediatric patients and shows that they have some characteristics different from ND occurring in adults. ND occurring in infants can be associated with a large spectrum of general diseases. Occurrence of neutrophilic disease is frequent in children. Thus, ND occurring in young paediatric patients should incite clinicians to schedule complementary explorations in order to search for involvement of other organs and to rule out monogenetic autoinflammatory syndromes., (© 2019 European Academy of Dermatology and Venereology.)
- Published
- 2019
- Full Text
- View/download PDF
6. Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.
- Author
-
Thomas AC, Zeng Z, Rivière JB, O'Shaughnessy R, Al-Olabi L, St-Onge J, Atherton DJ, Aubert H, Bagazgoitia L, Barbarot S, Bourrat E, Chiaverini C, Chong WK, Duffourd Y, Glover M, Groesser L, Hadj-Rabia S, Hamm H, Happle R, Mushtaq I, Lacour JP, Waelchli R, Wobser M, Vabres P, Patton EE, and Kinsler VA
- Subjects
- Alleles, Animals, Animals, Genetically Modified, Base Sequence, DNA Mutational Analysis, GTP-Binding Protein alpha Subunits, Gq-G11, HEK293 Cells, Humans, Infant, Molecular Sequence Data, Mutation, Missense, Phenotype, Phosphorylation, Signal Transduction, Zebrafish, GTP-Binding Protein alpha Subunits genetics, Mongolian Spot genetics, Mutation, Neurocutaneous Syndromes genetics, Skin Diseases genetics
- Abstract
Common birthmarks can be an indicator of underlying genetic disease but are often overlooked. Mongolian blue spots (dermal melanocytosis) are usually localized and transient, but they can be extensive, permanent, and associated with extracutaneous abnormalities. Co-occurrence with vascular birthmarks defines a subtype of phakomatosis pigmentovascularis, a group of syndromes associated with neurovascular, ophthalmological, overgrowth, and malignant complications. Here, we discover that extensive dermal melanocytosis and phakomatosis pigmentovascularis are associated with activating mutations in GNA11 and GNAQ, genes that encode Gα subunits of heterotrimeric G proteins. The mutations were detected at very low levels in affected tissues but were undetectable in the blood, indicating that these conditions are postzygotic mosaic disorders. In vitro expression of mutant GNA11(R183C) and GNA11(Q209L) in human cell lines demonstrated activation of the downstream p38 MAPK signaling pathway and the p38, JNK, and ERK pathways, respectively. Transgenic mosaic zebrafish models expressing mutant GNA11(R183C) under promoter mitfa developed extensive dermal melanocytosis recapitulating the human phenotype. Phakomatosis pigmentovascularis and extensive dermal melanocytosis are therefore diagnoses in the group of mosaic heterotrimeric G-protein disorders, joining McCune-Albright and Sturge-Weber syndromes. These findings will allow accurate clinical and molecular diagnosis of this subset of common birthmarks, thereby identifying infants at risk for serious complications, and provide novel therapeutic opportunities., (Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
7. [Skincare in premature newborn infants: a joint goal for dermatologists and neonatologists].
- Author
-
Barbarot S and Roze JC
- Subjects
- Dermatology, Humans, Iatrogenic Disease, Infant, Newborn, Intensive Care, Neonatal, Neonatology, Patient Care Team, Infant, Premature, Infant, Premature, Diseases therapy, Skin Diseases therapy
- Published
- 2015
- Full Text
- View/download PDF
8. [Skin manifestations of monoclonal gammopathies].
- Author
-
Hello M, Barbarot S, Néel A, Connault J, Graveleau J, Durant C, Decaux O, and Hamidou M
- Subjects
- Amyloidosis complications, Amyloidosis metabolism, Autoantibodies adverse effects, Autoantibodies metabolism, Autoimmune Diseases complications, Cryoglobulinemia complications, Cryoglobulinemia immunology, Cutis Laxa etiology, Cutis Laxa immunology, Humans, Immunoglobulins metabolism, POEMS Syndrome complications, POEMS Syndrome immunology, Paraproteinemias immunology, Paraproteinemias metabolism, Skin immunology, Skin metabolism, Skin Diseases immunology, Skin Diseases, Vesiculobullous immunology, Paraproteinemias complications, Skin Diseases etiology
- Abstract
Whatever their aetiology, monoclonal gammopathies can be associated to several clinical features. Mechanisms are various and sometimes unknown. Skin is frequently involved and may represent a challenging diagnosis. Indeed, skin manifestations are either the presenting features and isolated, or at the background of a systemic syndrome. Our objective was to review the various skin manifestations that have been associated with monoclonal gammopathies., (Copyright © 2013. Published by Elsevier SAS.)
- Published
- 2014
- Full Text
- View/download PDF
9. Ustekinumab therapy for severe interstitial granulomatous dermatitis with arthritis.
- Author
-
Leloup P, Aubert H, Causse S, Le Goff B, and Barbarot S
- Subjects
- Dermatitis complications, Dermatitis drug therapy, Dermatitis pathology, Granuloma complications, Granuloma pathology, Humans, Male, Middle Aged, Skin Diseases complications, Skin Diseases pathology, Ustekinumab, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Arthritis, Rheumatoid complications, Granuloma drug therapy, Skin Diseases drug therapy
- Published
- 2013
- Full Text
- View/download PDF
10. [Milia in children].
- Author
-
Barbarot S and Gagey-Caron V
- Subjects
- Beckwith-Wiedemann Syndrome pathology, Child, Humans, Hyperplasia, Male, Sweat Gland Neoplasms pathology, Syringoma pathology, Dermatoglyphics classification, Epidermal Cyst pathology, Skin Diseases pathology
- Published
- 2009
- Full Text
- View/download PDF
11. [Pyodermatitis-pyostomatitis vegetans with nasal involvement].
- Author
-
Peuvrel L, Barbarot S, Gagey-Caron V, Tessier MH, Cassagnau E, and Stalder JF
- Subjects
- Adult, Erythema pathology, Humans, Male, Mouth Mucosa drug effects, Pyoderma chemically induced, Skin Diseases chemically induced, Stomatitis chemically induced, Adrenal Cortex Hormones adverse effects, Mouth Mucosa pathology, Prednisone adverse effects, Pyoderma pathology, Skin Diseases pathology, Stomatitis pathology
- Abstract
Background: Pyodermatitis-pyostomatitis vegetans (PPV) is a rare chronic disorder often associated with inflammatory bowel disease. We report an isolated case involving the oral, labial and nasal mucosa., Patients and Methods: A 28-year-old man, in good general condition, presented with a 2-year history of painless stomatitis. The physical examination revealed pustular and exophytic lesions of the jugal, gingival and palatine mucosa on an erythematous background, as well as some pustular and crusted lesions of the lower lip and nostrils. Histopathological analysis revealed epithelial hyperplasia and a suprabasal cleft with some signs of acantholysis and numerous neutrophils and eosinophils. Direct and indirect immunofluorescence assay was negative. There was no associated bowel disease. We concluded on a diagnosis of PPV of younger subjects. The lesions disappeared with oral corticosteroids but with steroid dependency., Discussion: PPV is a rare dermatosis associated in more than 75% of cases with inflammatory bowel disease, usually ulcerative colitis. Lesions of the oral mucosa are a constant finding and are characterised by aseptic pustules on an erythematous background. Skin lesions are pustular and more or less exophytic. To our knowledge, there have been no reports to date of intranasal lesions of PPV.
- Published
- 2008
- Full Text
- View/download PDF
12. Two giant orf lesions in a heart/lung transplant patient.
- Author
-
Ballanger F, Barbarot S, Mollat C, Bossard C, Cassagnau E, Renac F, and Stalder JF
- Subjects
- Adult, Ecthyma, Contagious surgery, Humans, Immunosuppressive Agents administration & dosage, Male, Microscopy, Electron, Skin Diseases complications, Skin Diseases surgery, Tacrolimus administration & dosage, Ecthyma, Contagious complications, Heart-Lung Transplantation adverse effects, Skin Diseases diagnosis
- Abstract
Orf is an infectious ulcerative stomatitis of sheep and goats. The responsible pathogen, parapoxvirus, may be transmitted to humans. Orf lesions are often atypical in immunocompromised individuals. The present report describes two very large exophytic lesions in a 31-year-old transplant patient receiving oral tacrolimus, mycophenolate mofetil and prednisone. Early surgical excision was successful, with no relapse after 14 months.
- Published
- 2006
13. [Cutaneous lesions of the hands worsened by coldness].
- Author
-
Ballanger F, Barbarot S, Masseau A, Frot AS, and Hamidou M
- Subjects
- Adult, Female, Hand, Humans, Lupus Erythematosus, Systemic physiopathology, Skin Diseases physiopathology, Cold Temperature adverse effects, Lupus Erythematosus, Systemic diagnosis, Skin Diseases etiology
- Published
- 2005
- Full Text
- View/download PDF
14. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts.
- Author
-
Ring, J., Worm, M., Wollenberg, A., Thyssen, J.P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T., Bruin‐Weller, M.S., Chernyshov, P.V., Christen‐Zaech, S., Cork, M., Darsow, U., Flohr, C., Fölster‐Holst, R., Gelmetti, C., Gieler, U., Gutermuth, J., and Heratizadeh, A.
- Subjects
COVID-19 vaccines ,SKIN diseases ,ALLERGIES ,MEDICAL personnel ,ECZEMA ,PHYSICIANS - Abstract
Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non-financial support from LEO Pharma, Pierre Fabre, Sanofi-Genzyme and Bioderma. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
15. Skin manifestations of monoclonal gammopathies
- Author
-
Hello, M., Barbarot, S., Néel, A., Connault, J., Graveleau, J., Durant, C., Decaux, O., Hamidou, M., Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Interne, CHU Hotel Dieu, Centre Hospitalier Universitaire [Rennes], Département d'Hydraulique [M’Sila], and Université Mohamed Boudiaf de M'sila
- Subjects
integumentary system ,[SDV]Life Sciences [q-bio] ,Paraproteinemias ,Vesiculobullous ,Immunoglobulins ,Amyloidosis ,Skin Diseases ,Cutis Laxa ,Autoimmune Diseases ,Cryoglobulinemia ,POEMS Syndrome ,Humans ,Skin ,Autoantibodies - Abstract
National audience; Whatever their aetiology, monoclonal gammopathies can be associated to several clinical features. Mechanisms are various and sometimes unknown. Skin is frequently involved and may represent a challenging diagnosis. Indeed, skin manifestations are either the presenting features and isolated, or at the background of a systemic syndrome. Our objective was to review the various skin manifestations that have been associated with monoclonal gammopathies.
- Published
- 2014
16. What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials.
- Author
-
Nankervis, H., Thomas, K.S., Delamere, F.M., Barbarot, S., Smith, S., Rogers, N.K., and Williams, H.C.
- Subjects
ECZEMA ,SKIN inflammation ,SKIN diseases ,CALCINEURIN ,PHOSPHOPROTEIN phosphatases - Abstract
Atopic eczema ( AE) is a common chronic inflammatory skin condition. While many AE treatment options are available, the evidence to support their efficacy varies in depth and quality. In 2000, a National Institute for Health Research ( NIHR) Health Technology Assessment systematic review identified and evaluated existing randomized controlled trials ( RCTs) of AE treatments. To ensure continuing utility, the NIHR commissioned an update to the review. Here, we present an overview of the updated report and its key findings. Systematic reviews and RCTs of AE treatments that included participants with AE (criteria based or diagnosed) were identified using Medline, Embase, CENTRAL, Latin American and Caribbean Health Sciences, Allied and Complementary Medicine Database, Cumulative Index to Nursing and Allied Health Literature and Cochrane Skin Group Specialised Register [searched to 31 August 2013 ( RCTs) and 31 December 2015 (systematic reviews)]. Outcome measures included symptoms, AE severity, quality of life and adverse effects. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Of the 287 new RCTs identified, only 22 (8%) were judged to have a low risk of bias. When combined with RCTs from the previous review ( n = 254), we found 'reasonable evidence of benefit' for corticosteroids, calcineurin inhibitors, Atopiclair
® , ciclosporin, azathioprine, ultraviolet radiation and education programmes. Interventions with reasonable evidence of 'no benefit' included some dietary interventions, ion exchange water softeners, multiple daily applications of topical corticosteroids and antibiotic-containing corticosteroids for noninfected AE. Many common treatments lack evidence of efficacy and warrant further evaluation. The evidence base for AE is still hampered by poor trial design and reporting. The trials included in this review were used to establish the Global Resource of EczemA Trials ( GREAT) database. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
- Author
-
Chalmers, J.R., Simpson, E., Apfelbacher, C.J., Thomas, K.S., Kobyletzki, L., Schmitt, J., Singh, J.A., Svensson, Å., Williams, H.C., Abuabara, K., Aoki, V., Ardeleanu, M., Awici ‐ Rasmussen, M., Barbarot, S., Berents, T.L., Block, J., Bragg, A., Burton, T., Bjerring Clemmensen, K.K., and Creswell ‐ Melville, A.
- Subjects
ECZEMA ,SLEEP disorders ,ITCHING ,SKIN diseases ,SKIN inflammation - Abstract
This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema ( HOME) initiative held in Malmö, Sweden on 23-24 April 2015 ( HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema ( AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure ( POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Psoriasis and obesity in French children: a case-control, multicentre study.
- Author
-
Mahé, E., Beauchet, A., Bodemer, C., Phan, A., Bursztejn, A.‐C., Boralevi, F., Souillet, A.‐L., Chiaverini, C., Bourrat, E., Miquel, J., Vabres, P., Barbarot, S., Bessis, D., Eschard, C., and Hadj‐Rabia, S.
- Subjects
PSORIASIS ,SKIN diseases ,PSORIATIC arthritis ,CHILDHOOD obesity ,METABOLIC disorders in children - Abstract
Background Obesity is more common in adults with psoriasis than in the general population, but there is a lack of data available regarding this association in children. Objectives To evaluate whether obesity was more common in French children with psoriasis of any clinical type or severity. Methods A multicentre case-control study was performed in 23 French dermatology centres. Children without chronic or genetic inflammatory disease were selected as controls and matched for age, sex and dermatology centre. We used three weight cut-off categories to compare the two groups: overweight, overweight with abdominal obesity and overweight with obesity according to the French Health Authority guidelines. Results A total of 261 children with psoriasis were included. The mean age was 9.8 years, 126 were boys and 135 were girls. Overall, 42.5% of these children had plaque psoriasis and 32.2% had severe psoriasis. There was no difference between the psoriasis and control groups when the frequency of children who were overweight was compared (20·7% in psoriasis group vs. 17·1% in control group; P = 0·18). Overweight with abdominal obesity including obesity (18·4% vs. 10·4%; P = 0·009) and obesity alone (10·0% vs. 3·1%; P = 0·001) were more common in the psoriasis group. Conclusions This study shows that being overweight with abdominal obesity and being obese is more common in children with psoriasis than in controls. The risk factors are the same as those that affect the French general population, i.e. female sex and having a parent who was overweight. The severity and clinical type of psoriasis do not affect overweight and obesity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Manifestations cutanées associées aux gammapathies monoclonales.
- Author
-
Hello, M., Barbarot, S., Néel, A., Connault, J., Graveleau, J., Durant, C., Decaux, O., and Hamidou, M.
- Subjects
- *
CUTANEOUS manifestations of general diseases , *MONOCLONAL gammopathies , *SKIN diseases , *MEDICAL care research , *DIAGNOSIS - Abstract
Résumé: Les gammapathies monoclonales peuvent s’associer à diverses manifestations cliniques. Les mécanismes à l’œuvre sont variés et parfois mal compris. Parmi les manifestations cliniques associées aux gammapathies monoclonales, la peau est un organe fréquemment atteint. L’atteinte cutanée peut être inaugurale voire isolée. Elle peut aussi être discrète, au second plan d’un tableau systémique dont elle peut représenter un élément diagnostique majeur. Cette mise au point a pour objectif de passer en revue ces différentes manifestations cutanées. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Lower risk of atopic dermatitis among infants born extremely preterm compared with higher gestational age.
- Author
-
Barbarot, S., Gras ‐ Leguen, C., Colas, H., Garrot, E., Darmaun, D., Larroque, B., Roze, J.C., and Ancel, P.Y.
- Subjects
- *
ATOPIC dermatitis , *PREMATURE infant diseases , *GESTATIONAL age , *DURATION of pregnancy , *SKIN diseases , *DISEASE risk factors - Abstract
Background It is not yet known whether the risk of developing atopic dermatitis ( AD) is influenced by preterm birth. Moreover, AD risk has not been assessed in a large sample of extremely preterm infants (< 29 weeks' gestation). Objectives To determine whether the risk of AD is influenced by preterm birth. Methods We investigated the relationship between gestational age ( GA) and AD using data from two independent population-based cohorts, including a total of 2329 preterm infants, of whom 479 were born extremely preterm. Results There was a lower percentage of children with AD in the extremely preterm group compared with those born at a greater GA (Epipage cohort, 2-year outcome: 13·3% for 24-28 weeks, 17·6% for 29-32 weeks, 21·8% for 33-34 weeks, P = 0·02; LIFT cohort, 5-year outcome: 11% for 24-28 weeks, 21·5% for 29-32 weeks, 19·6% for 33-34 weeks, P = 0·11). After adjusting for confounding variables, a lower GA (< 29 weeks) was significantly associated with decreased risk of AD in the Epipage cohort [adjusted odds ratio ( aOR) 0·57, 95% confidence interval (CI) 0·37-0·87; P = 0·009] and the LIFT cohort ( aOR 0·41, 95% CI 0·18-0·90; P = 0·03). Conclusions Very low GA (< 29 weeks) was associated with a lower risk of AD compared with higher GA (29-34 weeks) and full-term birth. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Manifestations cutanées des thérapies ciblées
- Author
-
Hello, M., Barbarot, S., and Connault, J.
- Subjects
- *
SKIN diseases , *TUMOR necrosis factors , *HAND, foot & mouth disease , *PSORIASIS , *PARONYCHIA , *NAIL diseases - Abstract
Abstract: Many cutaneous adverse events have been identified with recently developed targeted treatments. Some of them are common and specific, like paradoxical psoriasiform eruptions with anti-TNFα, papulopustular eruptions and paronychias with EGFR inhibitors and peculiar hand-foot skin reactions with multitargeted kinase inhibitors sorefenib and sunitinib. Patients treated with these recently available biologics need a careful monitoring. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
22. Les manifestations buccofaciales de la sclérodermie systémique : étude de 30 patients consécutifs.
- Author
-
Vincent, C., Agard, C., Barbarot, S., N'Guyen, J.-M., Planchon, B., Durant, C., Pistorius, M.-A., Dreno, B., Ponge, T., Stalder, J.-F., Mercier, J.-M., and Hamidou, M.
- Subjects
SKIN diseases ,SYSTEMIC scleroderma ,SJOGREN'S syndrome ,ORAL manifestations of general diseases ,TRIGEMINAL neuralgia ,SCLERODERMA (Disease) ,PERIODONTAL ligament ,PATIENTS - Abstract
Copyright of Revue de Stomatologie & de Chirurgie Maxillo-Faciale is the property of Masson SPA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
23. Dermatoepidemiology; what's up people?
- Author
-
Nijsten, T., Apfelbacher, C., Gisondi, P., Silverberg, J., Cohen, A., Barbarot, S., Wakkee, M., and Ezzedine, K.
- Subjects
SKIN diseases ,EPIDEMIOLOGY ,MEDICAL care ,PREVENTIVE medicine ,DISEASE research - Abstract
The author argues in favor of dermatoepidemiology that aims to improve people's understanding of skin diseases, has clinical relevance and/or improves patient care and/or disease prevention. Topics discussed include the upside and downside of the hypothesis-generating aspect of epidemiological studies, the impact of the digital revolution on epidemiology, and the role of epidemiology in reporting and interpreting observational research. The future challenges for dermatoepidemiology are cited.
- Published
- 2015
- Full Text
- View/download PDF
24. Schnitzler syndrome: a dramatic improvement with anakinra.
- Author
-
Wastiaux, H., Barbarot, S., Gagey-Caron, V., Berthelot, J. M., Hamidou, M., and Stalder, J.-F.
- Subjects
- *
LETTERS to the editor , *SKIN diseases - Abstract
A letter to the editor is presented in response to an article related to the schnitzler syndrome.
- Published
- 2009
- Full Text
- View/download PDF
25. TREatment of ATopic eczema (TREAT) Registry Taskforce: method for comparing the safety of dupilumab with other systemic therapies for moderate‐to‐severe eczema.
- Author
-
Bosma, A.L., Spuls, P.I., Garcia‐Doval, I., Naldi, L., Prieto‐Merino, D., Tesch, F., Apfelbacher, C.J., Arents, B.W.M., Barbarot, S., Baselga, E., Deleuran, M., Eichenfield, L.F., Gerbens, L.A.A., Irvine, A.D., Manca, A., Mendes‐Bastos, P., Middelkamp‐Hup, M.A., Roberts, A., Seneschal, J., and Svensson, Å.
- Subjects
ATOPIC dermatitis ,SKIN diseases ,ECZEMA ,PHYSICIANS ,SAFETY ,THERAPEUTICS - Abstract
Summary: Atopic eczema (also called 'atopic dermatitis' or just 'eczema') is a common skin disease. Most people with atopic eczema can control their eczema with topical therapies (applied directly to the skin) such as emollients and topical corticosteroids. Some people, however, have moderate‐to‐severe disease that cannot be well managed with those therapies. Systemic therapy (acting on the whole body), with tablets or injections, is needed in these people to improve their symptoms effectively. Dupilumab is a new systemic medication (since 2018) for treating people with moderate‐to‐severe eczema. It has been approved both in the U.S.A. and the E.U. for people who are 12 years or older. In order to compare the safety of dupilumab with other systemic therapies, researchers need data on the safety of all those medications in real practice. The registries of the TREAT Registry Taskforce collect data on both the effectiveness and safety of all systemic therapies for atopic eczema. Countries such as the U.K., Ireland, the U.S.A., Germany, the Netherlands, Denmark, Sweden, France, Italy, Spain and Portugal are participating in TREAT. All those countries collect data the same way, so that the data are comparable. This article describes a protocol on how to use all these international data to compare the safety of dupilumab with other systemic treatments. This is important both for physicians and patients, to allow them to make informed decisions on which treatment is best for them. This is a summary of the study: TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema Linked Article: Bosma et al. Br J Dermatol 2020; 182:1423–1429 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Are adolescents with atopic eczema really undertreated in real life?
- Author
-
Barbarot, S.
- Subjects
- *
ECZEMA , *SKIN diseases , *SKIN inflammation , *STEROIDS , *DERMATOLOGY - Abstract
The article offers information on a study which deals with atopic eczema (AE) which is the most common chronic inflammatory skin disease. It mentions information on association between AE severity and the likelihood to use emollients and topical steroids. It states that topical steroids and emollients remain the mainstay of treatment but there are many barriers to medication adherence, including topical steroid phobia and the daily burden of complex topical treatments.
- Published
- 2018
- Full Text
- View/download PDF
27. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
- Author
-
Kwatra, S. G., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., Naldi, L., Lynde, C., De Bruin-Weller, M. S., Nahm, W. K., Sauder, M., Gharib, R., Barbarot, S., Szepietowski, J. C., Conrad, C., Fleischer, A., Laquer, V. T., Misery, L., Serra-Baldrich, E., and Lapeere, H.
- Subjects
- *
ITCHING , *CLINICAL trials , *PRURIGO , *SLEEP interruptions , *SUBCUTANEOUS injections , *SKIN diseases - Abstract
BACKGROUND Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmuno-logic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. METHODS In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to receive an initial 60-mg dose of nemolizumab followed by subcutaneous injections of 30 mg or 60 mg (depending on baseline weight) every 4 weeks for 16 weeks or matching placebo. The primary end points were an itch response (a reduction of ≥4 points on the Peak Pruritus Numerical Rating Scale [PP-NRS; scores range from 0 to 10, with higher scores indicating more severe itch]) and an Investigator's Global Assessment (IGA) response (a score of 0 [clear] or 1 [almost clear] on the IGA [scores range from 0 to 4] and a reduction from baseline to week 16 of ≥2 points). There were five key secondary end points. RESULTS A total of 274 patients underwent randomization; 183 were assigned to the nemolizumab group, and 91 to the placebo group. Treatment efficacy was shown with respect to both primary end points at week 16; a greater percentage of patients in the nemolizumab group than in the placebo group had an itch response (56.3% vs. 20.9%; strata-adjusted difference, 37.4 percentage points; 95% confidence interval [CI], 26.3 to 48.5), and a greater percentage in the nemolizumab group had an IGA response (37.7% vs. 11.0%; strata-adjusted difference, 28.5 percentage points; 95% CI, 18.8 to 38.2) (P<0.001 for both comparisons). Benefits were observed for the five key secondary end points: itch response at week 4 (41.0% vs. 7.7%), PP-NRS score of less than 2 at week 4 (19.7% vs. 2.2%) and week 16 (35.0% vs. 7.7%), and an improvement of 4 or more points on the sleep disturbance numerical rating scale (range, 0 [no sleep loss] to 10 [unable to sleep at all]) at week 4 (37.2% vs. 9.9%) and week 16 (51.9% vs. 20.9%) (P<0.001 for all comparisons). The most common individual adverse events were headache (6.6% vs. 4.4%) and atopic dermatitis (5.5% vs. 0%). CONCLUSIONS Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Syndrome de Sweet révélant une polychondrite atrophiante
- Author
-
Wastiaux, H., Hervier, B., Durant, C., Gagey-Caron, V., Masseau, A., Barbarot, S., and Hamidou, M.
- Subjects
- *
SWEET'S syndrome , *SKIN diseases , *CHONDROMALACIA , *CUTANEOUS manifestations of general diseases , *FOLLOW-up studies (Medicine) , *ADRENOCORTICAL hormones , *PATIENTS - Abstract
Abstract: Relapsing polychondritis (RP) is a rare disorder characterized by recurrent inflammatory episodes involving various cartilages. The clinical course of RP is variable, and dermatologic manifestations are uncommon. We report a 73-year-old patient who presented with a neutrophilic dermatosis (Sweet''s syndrome) as the initial manifestation of RP. There was no evidence for a myelodysplastic syndrome, as it has been previously reported with RP, but the patient was followed-up for an indolent and untreated chronic lymphocytic leukaemia. Complete remission was obtained with oral corticosteroids. This report highlights the clinical spectrum of the RP. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.